Northwest Biotherapeutics Sees Gains as it Receives Approval to Manufacture Immune Therapy in Germany (NWBO)

Northwest Biotherapeutics (OTC: NWBO), a biotech company based in Bethesda, Maryland, saw some slight gains again today after receiving approval for its immune therapy product. The company, which has experienced stock price increases all week, announced that its partner in Germany, Fraunhofer IZI, received approval and certification from the German equivalent of the United States’ Food and Drug Administration (FDA) to manufacture its DCVax-L immune therapy. In Europe, cell therapies are classified as advanced therapy medicinal products, and therefore must comply with strict regulations. The approval allows the company to proceed with clinical trials. The process for certification took 18 months to complete.

Northwest Biotherapeutics’ DCVax-L immune therapy works by combining a patient’s own dendritic cells with cancer-related proteins to induce immune responses against a patient’s cancer cells. It is designed to treat multiple cancers and can be used with other traditional cancer treatments, such as chemotherapy and radiation.

Northwest Biotherapeutics’ stock has been climbing the charts since July 18, 2012, when it closed at $0.2199. It has increased more than 40% since then. It closed at $0.308 last night and started the day at $0.319. After reaching $0.371, the stock closed at $0.316, earning a respectable 2.6% gain over yesterday. It is still only halfway to its highest point of $0.6208, which was attained almost a year ago today, on July 27, 2011. The company saw some prices in the $0.50 range in October 2011, but its stock activity has basically been a roller coaster ride since then.

Volume was more than quadruple the company’s daily average. Compared to the daily average volume of 253,382 shares, more than 1.26 million shares were traded today. In terms of volume, the company reached its 52-week high on March 27, 2012, when 1.48 million shares were traded. Volume exceeded the one-million mark several other times this year.

Penny stock newsletters heavily promoted Northwest Biotherapeutics throughout 2009 and 2010, with a few mentions last year. It also received some press in May 2012 after attaining consistent gains for several days straight. The company has not had much news to report except for today’s announcement. It will most likely need more positive company activity to keep the gains going in the long term.

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Lisa Ray

Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.